{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5(9)"],"submitter":["Zhou C"],"funding":["F. Hoffmann-La Roche","F. Hoffmann-La Roche Ltd"],"pubmed_abstract":["<h4>Introduction</h4>Previous results from the phase 3 ALESIA study (NCT02838420) revealed that alectinib (a central nervous system [CNS]-active, ALK inhibitor) had clinical benefits in treatment-naïve Asian patients with advanced <i>ALK</i>-positive NSCLC, consistent with the global ALEX study. We present updated data after more than or equal to 5 years of follow-up from the \"last patient in\" date.<h4>Methods</h4>Adult patients with treatment-naïve, advanced <i>ALK</i>-positive NSCLC from mainland China, South Korea, and Thailand were randomized 2:1 to receive twice-daily 600 mg alectinib (n = 125) or 250 mg crizotinib (n = 62). The primary endpoint was investigator-assessed progression-free survival. Secondary or exploratory endpoints included overall survival, objective response rate, t"],"journal":["JTO clinical and research reports"],"pagination":["100700"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11399573"],"repository":["biostudies-literature"],"pubmed_title":["Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Advanced <i>ALK</i>-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study."],"pmcid":["PMC11399573"],"pubmed_authors":["Kim SW","Bu L","Zhou M","Fang J","He J","Lu Y","Lee SH","Zhang L","Cheng Y","Hilton M","Yang JJ","Liu Z","Archer V","Zhou C","Zhang Y","Xu T","Reungwetwattana T","Chang J","Qian L","Zhou J"],"additional_accession":[]},"is_claimable":false,"name":"Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Advanced <i>ALK</i>-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study.","description":"<h4>Introduction</h4>Previous results from the phase 3 ALESIA study (NCT02838420) revealed that alectinib (a central nervous system [CNS]-active, ALK inhibitor) had clinical benefits in treatment-naïve Asian patients with advanced <i>ALK</i>-positive NSCLC, consistent with the global ALEX study. We present updated data after more than or equal to 5 years of follow-up from the \"last patient in\" date.<h4>Methods</h4>Adult patients with treatment-naïve, advanced <i>ALK</i>-positive NSCLC from mainland China, South Korea, and Thailand were randomized 2:1 to receive twice-daily 600 mg alectinib (n = 125) or 250 mg crizotinib (n = 62). The primary endpoint was investigator-assessed progression-free survival. Secondary or exploratory endpoints included overall survival, objective response rate, t","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2025-04-04T11:34:00.718Z","creation":"2025-04-04T11:34:00.718Z"},"accession":"S-EPMC11399573","cross_references":{"pubmed":["39282663"],"doi":["10.1016/j.jtocrr.2024.100700"]}}